pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

MedCity News

JANUARY 11, 2024

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Competition 122

Competition Sales Marketing Biopharma 122

The Marketing Advantage

MAY 8, 2023

Nevertheless, launching a rare disease product continues to be incredibly challenging; in extreme cases, companies have even chosen to cease all commercial sales efforts for their rare disease treatment. However, patients may see several physicians before being diagnosed, meaning a small sales force may need to service many physicians.

Sales 52

Sales Physicians Consulting Education 52

The Marketing Advantage

NOVEMBER 30, 2021

The severity and impact of the Omicron variant is still being assessed, forcing biopharma companies to grapple with immense uncertainty during one of the most important planning periods of the year, including 2022 sales incentive compensation planning. TERRITORY-LEVEL CONTINGENCY PLAN. 100%/80%) in order to make the territory whole.

Sales 52

Sales Biopharma Competition Medical 52

The Marketing Advantage

JULY 10, 2023

July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. Why Don’t Sales Representatives Follow Call Plans? Why Don’t Sales Representatives Follow Call Plans?

Sales 40

Sales Consulting Specialization Prospecting 40

The Marketing Advantage

SEPTEMBER 7, 2021

In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans. Bridging this increasingly growing divide is not easy and raises the question of what truly makes a sales compensation plan simple. ATTRIBUTE 2 Simple to administer. Simple to understand. Simple to administer.

Sales 52

Sales Biopharma Marketing Management 52

MedCity News

MARCH 30, 2023

The complaint alleges multiple violations of the Valentine Act, Ohio’s antitrust law, which prohibits price fixing, controlled sales and other agreements that restrain trade and hurt competition.

Competition 114

Competition Sales Biopharma 114

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 The company’s blockbuster immunotherapy oncology drug, Keytruda, a monoclonal antibody that targets PD-1, continues to reap record sales with an analyst consensus global sales forecast of $20.8 trillion to $3.61 to $365.84.

Marketing 78

Marketing Biopharma Sales Pharma 78

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Truly understanding the competitive landscape and market environment.

Competition 86

Competition Marketing Pharma Biopharma 86

European Pharmaceutical Review

JUNE 15, 2023

Sales in the small molecule innovator CDMO market is expected to grow at a compound annual growth rate (CAGR) of 6.4 Accelerating advancement of research and technology in biopharma are generating opportunities for the industry to develop innovative small molecule drugs. billion in 2023 and $89.43 billion in 2033.

Marketing 52

Marketing Competition Manufacturing Biopharma 52

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Mirati has declined to comment on the speculation.

Pharma 100

Pharma Biopharma FDA Competition 100

MedCity News

OCTOBER 12, 2023

European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.

Sales 117

Sales Competition Biopharma 117

The Marketing Advantage

MARCH 9, 2021

March 9, 2021 Critical to optimizing sales force productivity and efficiency is identifying the right HCP and/or account targets. However, in the complex pharma, biotech and medical device landscape, the easy way of targeting HCPs is, unfortunately, not the right way in most circumstances, and ultimately diminishes sales and adoption.

Sales 52

Sales Competition Marketing Biopharma 52

pharmaphorum

JANUARY 3, 2023

The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. ” The new data could accelerate partnering efforts of the drug this year.

Side effects 102

Side effects Biopharma Patients Competition 102

Pharmaceutical Technology

JUNE 29, 2022

According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Now, due to the highly competitive environment, the process is truncated to 12-18 months.

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Quantified

JANUARY 3, 2023

You are going to see a dramatic change in leadership’s urgency to leverage AI This new creative AI era will fuel massive advances in personalized customer service, drive new business models, improve real-time modeling ( Southwest Airlines ) and pave the way for breakthroughs in healthcare and biopharma from Google ‘s DeepMind.

Biopharma 40

Biopharma Media Competition Training 40

Clarivate

JANUARY 23, 2024

forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.

Pharma 104

Pharma Pharmaceutical manufacturing Pharmaceutical Manufacturing 104

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Under buy and bill (B&B) in Medicare Part B, physician practices profit from reimbursement (historically Average Sales Price + 6% before sequestration) as well as rebates and discounts negotiated with manufacturers for hitting volume levels.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 27, 2023

There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” Bates continued: “We expected a fall in investment following two bumper years, but it should still be considered a warning.

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Pharmaceutical Technology

NOVEMBER 23, 2022

The US still dominates the biopharma sector with more than $378bn in annual drug sales and an approximate capacity of 30% of global manufacturing. Hamilton offers more competitive prices than Toronto and the city is only an hour away from its larger neighbour. City Competitiveness Index. ft2 in Toronto 1.

Marketing 52

Marketing Manufacturing Transportation Government 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

The Marketing Advantage

NOVEMBER 13, 2023

November 13, 2023 Two critical elements that inform how biopharma sales representatives sell to HCPs are (1) the prescribing behavior exhibited by the HCP, or behavioral segment , and (2) the HCP’s loyalty to the products they prescribe. Consider a dominant single prescriber. make the prescriber become a dominant dual prescriber).

Consulting 52

Consulting Biopharma Sales Competition 52

pharmaphorum

JANUARY 24, 2023

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

Manufacturing 104

Manufacturing Medicine Government Pharmaceutical manufacturing 104

Clarivate

DECEMBER 14, 2023

With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. The arrival of a second drug may drive PBMs to expand coverage in exchange for aggressive rebates.

Marketing 52

Marketing Healthcare Healthcare Insurance 52